%D9%85%D8%AA%D9%84%D8%A7%D8%B2%D9%85%D8%A9_%D8%A3%D8%B6%D8%AF%D8%A7%D8%AF_%D8%A7%D9%84%D9%81%D9%88%D8%B3%D9%81%D9%88%D9%84%D9%8A%D8%A8%D9%8A%D8%AFAntiphospholipid-SyndromAntiphospholipid_syndromeS%C3%ADndrome_antifosfol%C3%ADpido%D9%86%D8%B4%D8%A7%D9%86%DA%AF%D8%A7%D9%86_%D8%A2%D9%86%D8%AA%DB%8C_%D9%81%D8%B3%D9%81%D9%88%D9%84%DB%8C%D9%BE%DB%8C%D8%AFSyndrome_des_antiphospholipides%D7%AA%D7%A1%D7%9E%D7%95%D7%A0%D7%AA_%D7%90%D7%A0%D7%98%D7%99-%D7%A4%D7%95%D7%A1%D7%A4%D7%95%D7%9C%D7%99%D7%A4%D7%99%D7%93%D7%99%D7%AA%D5%80%D5%A1%D5%AF%D5%A1%D6%86%D5%B8%D5%BD%D6%86%D5%B8%D5%AC%D5%AB%D5%BA%D5%AB%D5%A4%D5%A1%D5%B5%D5%AB%D5%B6_%D5%B0%D5%A1%D5%B4%D5%A1%D5%AD%D5%BF%D5%A1%D5%B6%D5%AB%D5%B7Sindrom_antibodi_antifosfolipidSindrome_da_anticorpi_antifosfolipidi%E6%8A%97%E3%83%AA%E3%83%B3%E8%84%82%E8%B3%AA%E6%8A%97%E4%BD%93%E7%97%87%E5%80%99%E7%BE%A4Antifosfolipidinis_sindromasAntifosfolip%C4%ABdu_sindromsAntifosfolipidensyndroomZesp%C3%B3%C5%82_antyfosfolipidowyS%C3%ADndrome_do_anticorpo_antifosfolip%C3%ADdeo%D0%90%D0%BD%D1%82%D0%B8%D1%84%D0%BE%D1%81%D1%84%D0%BE%D0%BB%D0%B8%D0%BF%D0%B8%D0%B4%D0%BD%D1%8B%D0%B9_%D1%81%D0%B8%D0%BD%D0%B4%D1%80%D0%BE%D0%BC%D0%90%D0%BD%D1%82%D0%B8%D1%84%D0%BE%D1%81%D1%84%D0%BE%D0%BB%D0%B8%D0%BF%D0%B8%D0%B4%D0%BD%D0%B8_%D1%81%D0%B8%D0%BD%D0%B4%D1%80%D0%BE%D0%BCAntifosfolipidsyndrom%E0%B8%81%E0%B8%A5%E0%B8%B8%E0%B9%88%E0%B8%A1%E0%B8%AD%E0%B8%B2%E0%B8%81%E0%B8%B2%E0%B8%A3%E0%B9%81%E0%B8%AD%E0%B8%99%E0%B9%84%E0%B8%97%E0%B8%9F%E0%B8%AD%E0%B8%AA%E0%B9%82%E0%B8%9F%E0%B9%84%E0%B8%A5%E0%B8%9B%E0%B8%B4%E0%B8%94%D0%90%D0%BD%D1%82%D0%B8%D1%84%D0%BE%D1%81%D1%84%D0%BE%D0%BB%D1%96%D0%BF%D1%96%D0%B4%D0%BD%D0%B8%D0%B9_%D1%81%D0%B8%D0%BD%D0%B4%D1%80%D0%BE%D0%BCH%E1%BB%99i_ch%E1%BB%A9ng_kh%C3%A1ng_phospholipidQ582207%E6%8A%97%E7%A3%B7%E8%84%82%E7%97%87%E5%80%99%E7%BE%A4
about
sameAs
Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid SyndromeRIvaroxaban for Stroke Patients With AntiPhospholipid SyndromeEvaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL)Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid SyndromeThe Value of Placental Vascularization and Placental Volume in Pregnancy in APLSAntiphospholipid Antibodies and Fetal Growth RestrictionAntiphospholipid Antibodies and Early Severe Preeclampsia.Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)Medium-term Follow-up of Patients With Obstetric Antiphospholipid Syndrome: MRI Study of White MatterMeasurement of Anti-dsDNA by Both CLIFT & ELISANew Biological Tests in Patients With Antiphospholipid AntibodiesSafety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic DiseasesPreconceptional Thromboprophylaxis in Recurrent PREGNANCY LOSSES Caused by Antiphospholipid SyndromeMonitoring Anticoagulant Therapy in Antiphospholipid SyndromeCI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and AcetaminophenComparative Prevalence of Psychiatric Manifestations in Purely Obstetrical Antiphospholipid SyndromeEffects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome PatientsSpontaneous Coronary Artery Dissection (SCAD) and AutoimmunityStudy of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid SyndromeOmega 3 in LES and APSPregnancy and Medically Assisted Conception in Rare DiseasesUse of Warfarin After the First Trimester in Pregnant Women With APSApixaban for the Secondary Prevention of Thromboembolism Among Patients With the AntiphosPholipid SyndromeThe Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic SyndromePilot Study of Gut Commensals in Antiphospholipid SyndromeHydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive PatientsDrug Interaction Between Paracetamol and WarfarinLow-molecular-weight Heparin (LMWH) Versus Unfractionated Heparin (UFH) in Pregnant Women With Recurrent Abortion Secondary to Antiphospholipid SyndromeEculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody SyndromeReliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With WarfarinRegister for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally StudyMulti-organ Screening for Asymptomatic Ischaemia in Antiphospholipid SyndromePrevalence of Antiphospholipid Antibodies in the Hemodialysis Patients Population Within the CHU Brugmann HospitalOcular Findings in Women With Primary Antiphospholipid SyndromePrevalence of Lysosomal Hydrolase Alpha-glagtosidase Deficiency in Patients With Antiphospholipid Syndrome.Timing of Initiation of LMWH Administration in Pregnant Women With APSRivaroxaban in Thrombotic Antiphospholipid SyndromeRivaroxaban for Antiphospholipid Antibody SyndromeCoaguChek XS in Antiphospholipid Antibody Syndrome (APL) PatientsLow Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss: A RCT
P1050
Impact of Antiphospholipid Syndrome and/or Systemic Lupus Erythematosus on the Long-term Adverse Cardiovascular Outcomes in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysisRheumatic fever associated with antiphospholipid syndrome: systematic reviewObstetrical antiphospholipid syndrome: from the pathogenesis to the clinical and therapeutic implicationsThe Role of TLR4 on B Cell Activation and Anti-β2GPI Antibody Production in the Antiphospholipid SyndromeThe Role of Complement Inhibition in Thrombotic Angiopathies and Antiphospholipid Syndrome.Antibodies to serine proteases in the antiphospholipid syndrome.EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndromeAntiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers.Cardiovascular risk factors in the antiphospholipid syndromeAntiphospholipid syndrome; its implication in cardiovascular diseases: a review.Autoantibodies directed against domain I of beta2-glycoprotein I.The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome"New" antigenic targets and methodological approaches for refining laboratory diagnosis of antiphospholipid syndromeAcute myocardial infarction in young adults with antiphospholipid syndrome: report of two cases and literature review.Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches.Antiphospholipid syndrome and vascular ischemic (occlusive) diseases: an overview.Revisiting the molecular mechanism of neurological manifestations in antiphospholipid syndrome: beyond vascular damage.Renal Involvement in Antiphospholipid Syndrome.Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome.Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment.An approach to differential diagnosis of antiphospholipid antibody syndrome and related conditionsβ2-Glycoprotein I-Reactive T Cells in Autoimmune Disease
P921
Q61894568-EBE2D9C2-57E4-4672-B506-BEFF7290109AQ62054646-E3E41DE3-F362-4B54-B49D-A2B72DD87AC6Q62054816-12C014A9-E642-4F13-A94C-E121A1004F2CQ62812040-89A464C0-8595-4DC9-B477-EB708B164AFCQ62823256-D299BA2D-F78B-434A-8EB6-A13A35A5208DQ63319873-F2438362-FD61-4B11-8C56-ED8B1E391CF9Q63319877-58502AC8-6AFF-4E6F-AA9C-B99C3A2F83C8Q63321117-EE4C51AC-C6BD-4347-A623-802CC5C745ECQ63394298-F31E5360-2943-486B-951A-90ADD0AA4382Q63575157-10094A6A-25D2-4E1C-9661-BFBA27AA1425Q63587165-DD843D6C-0306-4270-9541-31F1F9F9D1DAQ63829439-4870CE50-A4E4-451F-AD52-1260D7858DA9Q63839365-C20139B9-9749-4B91-A4EA-54EBED4A2867Q63839823-EDE8F60A-5764-40AA-B106-972ABA21DA73Q63845085-513FDF77-290D-4CC9-BEA8-92ED8D29083AQ64030028-40C17F60-51A4-421E-8CFB-F0AD95689C50Q64047078-5CC3EAAF-B525-407E-BC3B-3ABF4540B4C5Q64188879-77943694-5B60-41D4-AA94-FDC5E18FDE0DQ64216777-D0646A3D-F119-4DA0-A89E-D6C16181CDCAQ64353635-683D2EC6-9140-46D2-BB38-845A46FE548DQ64375254-F6023DB9-73F3-4336-942A-124D613A19DCQ64598817-4EDE0692-7A90-4EC1-8610-092E9924152EQ64613763-A5E8A201-BEEB-42A8-9139-8E3D27B16439Q64625308-B8439999-141D-4166-80C0-EEAD2D64F4AFQ64635855-4504A48B-A5CA-4C52-BDBD-4D28EF878C88Q64636362-6867688D-4F6A-4DE9-AFBC-C714BE18188DQ64655917-42E2C438-BE6C-4C10-80B8-F18A6706B7FDQ64657291-C47E9189-01A1-480D-BBCA-7F523C33C332Q64683920-98435D6B-D4D0-4F8B-9442-0BBA1B48A318Q64707593-AA559CC0-F08E-4533-8DEE-F01C3E337749Q64723371-1906416A-285A-4385-8247-C1193B6715BBQ64788929-829F3F76-0039-4339-8A84-630C11EF9656Q64794539-E6D79946-7239-4B2C-8089-E71F55C2F5E2Q64802015-8381AB80-4C15-471B-9ADE-D6A6B3B9DE64Q64804976-20D306FC-E36D-4BC5-B39D-CCBD17C223A0Q65352315-CB0C0549-86E8-47C7-8E57-CC28994A969FQ65355503-DBE86668-04D4-4173-83CB-D89181363768Q65357587-356C04D5-4493-4850-9B77-F5F431E0E975Q65357953-91E493D8-5797-41EC-8C29-A3A46C00F33DQ65379184-57C4DE01-60DA-437C-9DDD-EE279F2F6CAE
P1050
Q26750752-2BF479A6-2DAD-4504-8623-F677C7608C38Q26859847-E35E98D1-01A8-4E64-9692-573D48E1B558Q26998188-C7CB2FA2-678D-4600-AD22-7040968D9003Q28069430-1A4534B7-12FE-4BE5-9A0C-DF081EC3E1D5Q33431097-EEA8FB32-3236-4C10-80AC-49CE980650CFQ33670367-2B46BFED-5D07-47D5-AB0F-8368DE7D764FQ33731711-9F0E2731-338B-4304-BD06-D6A0FB31B5E6Q33766670-90375903-2D75-40EC-837F-108A3177541CQ34003460-7C1F32E0-DED2-4189-A73B-5ABE456E5688Q34331685-CC6D28BE-BCFF-46C4-BA48-8056467C78A1Q34467454-FAC7B210-945C-4F62-BD3A-768DB2E1FB22Q34966670-30ABC8DA-4E65-4B26-A258-705CDCCF2D5DQ35250419-C8FE1416-D7B8-4924-8076-CBFCDE59FCD2Q35444451-EFB92D7E-BC84-4FB2-BD3B-61B0AFAE9B44Q35621012-4D4037EE-77CC-42EB-BEDF-489F741F7463Q37045158-B55EE8BA-B8E8-4B95-94B2-2A8CDEED0FF5Q37704593-43F20444-9CCB-4695-A903-265A246E1C90Q54967401-1D9ED8AA-EF8B-4223-B824-44DE39301894Q54996884-C3DE03BA-7E91-479C-B05F-D34EAEF4DD81Q55177568-BB27E2D2-27C7-441B-8C8F-25E2058D71B6Q59075500-E9008466-4AB7-4809-934A-DBFFF2DFB610Q60961044-AA656E72-05A0-4BD3-88EF-192111143CF7
P921
description
Human disease
@en
Krankheit
@de
SAPL
@fr
autoimmun sjukdom
@nn
choroba związana z obecnością autoprzeciwciał i zakrzepicą/poronieniami
@pl
malattia autoimmune, definita ...... e arteriose, ma anche entrambe
@it
антифосфолипидный синдром
@ru
аутоімунне захворювання
@uk
مرض يصيب الإنسان
@ar
name
Antifosfolipidensyndroom
@nl
Antifosfolipidinis sindromas
@lt
Antifosfolipīdu sindroms
@lv
Antiphospholipid-Syndrom
@de
Hội chứng kháng phospholipid
@vi
Sindrom antibodi antifosfolipid
@id
Syndrome des antiphospholipides
@fr
Síndrome antifosfolípidos
@es
Zespół antyfosfolipidowy
@pl
antifosfolipidsyndrom
@nn
type
label
Antifosfolipidensyndroom
@nl
Antifosfolipidinis sindromas
@lt
Antifosfolipīdu sindroms
@lv
Antiphospholipid-Syndrom
@de
Hội chứng kháng phospholipid
@vi
Sindrom antibodi antifosfolipid
@id
Syndrome des antiphospholipides
@fr
Síndrome antifosfolípidos
@es
Zespół antyfosfolipidowy
@pl
antifosfolipidsyndrom
@nn
altLabel
APA-Syndrom
@de
APL-syndrom
@nn
APLA
@he
APLS
@he
APLS
@nn
APS
@id
APS
@nn
APS
@pl
Anti-Phospholipid-Syndrom
@de
Anti-phospholipid antibody syndrome
@ja
prefLabel
Antifosfolipidensyndroom
@nl
Antifosfolipidinis sindromas
@lt
Antifosfolipīdu sindroms
@lv
Antiphospholipid-Syndrom
@de
Hội chứng kháng phospholipid
@vi
Sindrom antibodi antifosfolipid
@id
Syndrome des antiphospholipides
@fr
Síndrome antifosfolípidos
@es
Zespół antyfosfolipidowy
@pl
antifosfolipidsyndrom
@nn
P486
P646
P672
P1325
P1461
Antiphospholipid-syndrome
P1692
P1748
P1995
P2892
P3417
Antiphospholipid-Syndrome
P3827
antiphospholipid-antibodies
antiphospholipid-syndrome
P4229
P486
P492
P5082
antifosfolipidsyndrom